SARS-CoV-2 (COVID-19) 3CL-Mpro Protein, His-Tag
Cysteine protease 3CL-Mpro of SARS-CoV-2 (COVID-19) that cleaves the transcribed viral polyprotein into several functional proteins at two self-cleavage sites.
Order Details
- 100µg – 390€
- more on request – bulk and gram quantities available
Shipped next working day, depending on destination
Overview
Sequence Information
Species | SARS-CoV-2; Wuhan seafood market pneumonia virus |
Tags | N-terminal |
Sequence without tags (AA 1-306) | SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYEDLLIR KSNHNFLVQAGNVQLRVIGHSMQNCVLKLKVDTANPKTPKYKFVRIQPGQTFSVLACYNG SPSGVYQCAMRPNFTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELPTGVHAGTDLEGN FYGPFVDRQTAQAAGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYE PLTQDHVDILGPLSAQTGIAVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRQC SGVTFQ |
Product Information
Expression Host | E. coli |
Formulation | PBS, pH 7.4; contains Glycerol as protectant |
Format | Liquid, stored and shipped at -80°C |
Purity |
> 90% as determined by SDS-PAGE |
Background Information
The new coronavirus SARS-CoV-2 expresses two proteases, the papain-like protease (PLpro) and 3C-like protease (3CLpro). Both belong to the group of cysteine proteases, as they have a cysteine residue at their catalytic site. Their main function is the processing of the viral polyprotein, that contains two cleavage sites to build up the viral replicase complex. Additionally, PLpro has the ability of removing ISG15 and ubiquitin from viral proteins expressed in the cell, this enables evasion from the innate immune response by the host. This represents an interesting target for drug development. This is because it not only would inhibit viral replication, but would also prevent the massive immunological response that results from the over-activation of the host’s immune system. Such an over-activation can lead to damage of the uninfected cells and thus to a worsening of the patient’s condition. N-terminal His-tag may interfere with activity of protein. If activity is crucial, please choose the tag-free variant (Cat. No. P2020-019) or the unmodified variant with authentic N-terminus (Cat. No. P2020-027). |
Further recombinant SARS-CoV-2 proteins

Reinhold Horlacher, PhD
Managing Director & CSO
We would be happy to provide you with your desired protein and to support you on your protein research project. If you have any questions or requests, our scientific experts will be happy to answer them shortly.
Get In Contact With Our Scientific Experts For Your Executable Quote Or Your Bulk Order